Daiichi Sankyo (OTCMKTS:DSNKY) Reaches New 12-Month Low – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $17.52 and last traded at $17.55, with a volume of 14378 shares changing hands. The stock had previously closed at $18.59.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Daiichi Sankyo Trading Up 3.0%

The company has a 50 day moving average of $20.10 and a 200 day moving average of $22.63. The firm has a market cap of $34.84 billion, a P/E ratio of 16.87, a PEG ratio of 1.08 and a beta of -0.35. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.05. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. The business had revenue of $3.65 billion during the quarter, compared to analyst estimates of $3.88 billion. Analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.73 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.